Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Quest Diagnostics (DGX) and Merck & Company (MRK)

Tipranks - Tipranks - Thu Apr 23, 7:06AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Intuitive Surgical (ISRG), Quest Diagnostics (DGX) and Merck & Company (MRK).

Claim 30% Off TipRanks

Intuitive Surgical (ISRG)

Truist Financial analyst Richard Newitter maintained a Buy rating on Intuitive Surgical today. The company’s shares closed last Tuesday at $451.29.

According to TipRanks.com, Newitter is a 4-star analyst with an average return of 7.9% and a 46.8% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Treace Medical Concepts, and Zimmer Biomet Holdings. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intuitive Surgical with a $601.32 average price target, a 28.2% upside from current levels. In a report issued on April 13, RBC Capital also maintained a Buy rating on the stock with a $650.00 price target.

See the top stocks recommended by analysts >>

Quest Diagnostics (DGX)

Truist Financial analyst David S Macdonald maintained a Hold rating on Quest Diagnostics today. The company’s shares closed last Tuesday at $205.04.

According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 9.8% and a 57.0% success rate. Macdonald covers the Healthcare sector, focusing on stocks such as Guardian Pharmacy Services, Inc. Class A, Concentra Group Holdings Parent, Inc., and Ardent Health Partners, Inc. ;'>

Quest Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $221.00, representing an 8.7% upside. In a report released yesterday, TipRanks – xAI also downgraded the stock to Hold with a $212.00 price target.

Merck & Company (MRK)

BMO Capital analyst Evan Seigerman maintained a Buy rating on Merck & Company yesterday and set a price target of $135.00. The company’s shares closed last Tuesday at $112.56.

According to TipRanks.com, Seigerman is a 5-star analyst with an average return of 9.0% and a 52.1% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and Taysha Gene Therapies. ;'>

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $134.55, implying a 15.5% upside from current levels. In a report issued on April 6, J.P. Morgan also maintained a Buy rating on the stock with a $135.00 price target.

Read More on ISRG:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).